View Older Stories View More Recent Stories

Nov 4, 2021 07:00AM Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)
Nov 4, 2021 07:00AM Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Bil
Oct 25, 2021 07:30AM More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood P
Oct 21, 2021 07:00AM Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
Sep 2, 2021 07:30AM Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
Aug 26, 2021 07:04AM Ironwood Pharma (IRWD) Announces FDA Approval of Updated LINZESS® Label
Aug 26, 2021 07:00AM Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
Aug 5, 2021 07:00AM Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
Aug 3, 2021 07:30AM Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
Jul 22, 2021 04:01PM Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
Jun 16, 2021 07:46AM Ironwood Pharma (IRWD) Announces American Journal of Gastroenterology Publishes Full Results from Positive LINZESS Phase IIIb Trial in Adults with IBS-C
Jun 16, 2021 07:45AM Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome w
Jun 7, 2021 04:02PM Ironwood Pharma (IRWD) announces Thomas McCourt named permanent CEO and appointed to Board, Gina Consylman to step down as SVP, CFO
Jun 7, 2021 04:01PM Ironwood Pharmaceuticals Announces Leadership Updates
May 26, 2021 04:10PM Ironwood Pharma (IRWD) Announces Agreement with Teva (TEVA) Involving LINZESS (linaclotide) 72 mcg Dosage Strength
May 26, 2021 04:01PM Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
May 24, 2021 08:00AM More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (D
May 17, 2021 08:30AM Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
May 6, 2021 07:03AM Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
May 6, 2021 07:00AM Ironwood Pharmaceuticals Reports First Quarter 2021 Results
Apr 22, 2021 04:01PM Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
Feb 19, 2021 04:01PM Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 17, 2021 07:01AM Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
Feb 8, 2021 04:04PM Ironwood Pharma (IRWD) Announces CEO Transition
Feb 8, 2021 04:01PM Ironwood Pharmaceuticals Announces CEO Transition
Feb 3, 2021 04:01PM Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
Jan 5, 2021 07:30AM Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 3, 2020 08:32AM Ironwood Pharma (IRWD) Announces Jay P. Shepard to Board
Dec 3, 2020 08:30AM Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
Nov 6, 2020 04:01PM Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
Nov 5, 2020 04:03PM Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
Nov 5, 2020 04:01PM Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors
Oct 22, 2020 04:01PM Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
Sep 29, 2020 07:16AM Ironwood Pharma (IRWD) to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
Sep 29, 2020 07:15AM Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
Sep 2, 2020 04:00PM Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
Aug 6, 2020 07:00AM Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
Jul 23, 2020 04:05PM Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
Jul 21, 2020 07:09AM Ironwood Pharma (IRWD) Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory GERD
Jul 21, 2020 07:00AM Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
May 27, 2020 08:08AM Ironwood Pharma (IRWD), AbbVie (ABBV) Report Top-Line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with IBS-D
May 27, 2020 08:00AM Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
May 6, 2020 04:05PM Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
Apr 28, 2020 04:05PM Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
Apr 16, 2020 04:05PM Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call
Mar 26, 2020 09:03AM Ironwood Pharma (IRWD) Provides Update on Impact of COVID-19
Mar 26, 2020 09:00AM Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
Feb 26, 2020 05:10PM Ironwood Pharma (IRWD) Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
Feb 26, 2020 04:05PM Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
Feb 25, 2020 04:05PM Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
View More Recent Stories View Older Stories